Precigen Earnings Call Transcripts
Fiscal Year 2026
-
PAPZIMEOS, the first immunotherapy for adult RRP, is driving a commercial transformation, with strong launch metrics, broad physician support, and robust payer access. The company is expanding its pipeline with pediatric trials, redosing studies, and new cancer indications leveraging its differentiated platform.
-
A proprietary adenovirus platform enabled rapid development and full FDA approval of Pepcimeus for RRP, shifting care from surgery to a medical standard. Commercial launch saw swift market penetration, strong payer coverage, and broad physician adoption, with ex-U.S. expansion and cash flow positivity targeted by year-end.
Fiscal Year 2025
-
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 revenue expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, while European expansion and pediatric trials are underway.
-
PAPZIMEOS secured full FDA approval and launched as the first therapy for adult RRP, showing strong efficacy, safety, and rapid commercial uptake. Q3 ended with $123.6M in cash, and breakeven is targeted by end of 2026, supported by robust demand and payer coverage.
-
PAPZIMEOS, a first-in-class therapy for recurrent respiratory papillomatosis, received early FDA approval and is set for a broad U.S. launch. The company is expanding indications, has a strong financial runway, and is transitioning to a commercial biopharma model.
-
Papzimeos received full FDA approval as the first and only therapy for adult RRP, with a broad label and strong efficacy. The launch targets over 90% of the patient population, supported by robust infrastructure, financial assistance, and close collaboration with advocacy groups.
-
A novel gene therapy for RRP is on track for FDA approval in 2025, supported by strong efficacy, safety, and commercial readiness. The company is also advancing its UltraCAR-T platform and expects key regulatory and partnership milestones this year.
Fiscal Year 2024
-
PRGN-2012 advanced rapidly to FDA priority review, with pivotal data showing 51% durable complete response in RRP. Financially, a $126.2M net loss was offset by new funding, supporting operations into 2026 as commercialization preparations accelerate.
-
The discussion highlighted a novel gene therapy platform advancing toward BLA submission for RRP, with strong efficacy, safety, and commercial prospects. The therapy offers significant differentiation from current treatments and competitors, and pipeline expansion is planned for other indications.
-
PRGN-2012 showed strong efficacy and safety in RRP, with 51% complete response and 86% surgery reduction. The company is prioritizing this asset, streamlining operations, and preparing for a 2025 launch, supported by recent financing and global ambitions.
-
PRGN-2012 demonstrated a 51% complete response rate in RRP patients, with durable benefit and a strong safety profile. The therapy is advancing toward a 2025 commercial launch, supported by FDA designations and ongoing confirmatory trials.